Role of NFkappaB in the mortality of sepsis

H Böhrer, F Qiu, T Zimmermann, Y Zhang, T Jllmer, D Männel, B W Böttiger, D M Stern, R Waldherr, H D Saeger, R Ziegler, A Bierhaus, E Martin, P P Nawroth, H Böhrer, F Qiu, T Zimmermann, Y Zhang, T Jllmer, D Männel, B W Böttiger, D M Stern, R Waldherr, H D Saeger, R Ziegler, A Bierhaus, E Martin, P P Nawroth

Abstract

Binding activity for nuclear factor kappa B (NFkappaB) consensus probes was studied in nuclear extracts from peripheral blood mononuclear cells of 15 septic patients (10 surviving and 5 not surviving). Nonsurvivors could be distinguished from survivors by an increase in NFkappaB binding activity during the observation period (P < 0.001). The increase in NFkappaB binding activity was comparable to the APACHE-II score as a predictor of outcome. Intravenous somatic gene transfer with an expression plasmid coding for IkappaBalpha was used to investigate the role of members of the NFkappaB family in a mouse model of endotoxemia. In this model, increased NFkappaB binding activity was present after injection of LPS. Intravenous somatic gene transfer with IkappaBalpha given before LPS attenuated renal NFkappaB binding activity and increased survival. Endothelial cells and monocytes/macrophages were the major target cells for somatic gene transfer, transfected with an average transfection efficiency of 20-35%. Tissue factor, a gene under regulatory control of NFkappaB, was induced by LPS. Somatic gene transfer with a reporter plasmid containing the functional tissue factor promoter demonstrated NFkappaB-dependent stimulation by LPS. Intravenous somatic gene transfer with IkappaBalpha reduced LPS-induced renal tissue factor expression, activation of the plasmatic coagulation system (decrease of thrombin-antithrombin III complexes) and renal fibrin/fibrinogen deposition. Somatic gene transfer with an expression plasmid with tissue factor cDNA in the antisense direction (in contrast to sense or vector alone) also increased survival. Furthermore, antisense tissue factor decreased renal tissue factor expression and the activation of the plasmatic coagulation system.

References

    1. Blood. 1990 Apr 1;75(7):1481-9
    1. J Surg Res. 1996 Jul 15;64(1):95-101
    1. J Clin Invest. 1991 Mar;87(3):894-900
    1. Cell. 1991 Mar 8;64(5):961-9
    1. Nucleic Acids Res. 1991 May 11;19(9):2499
    1. Circ Shock. 1991 Mar;33(3):127-34
    1. Immunology. 1991 Aug;73(4):460-5
    1. Proc Natl Acad Sci U S A. 1991 Dec 1;88(23):10535-9
    1. J Exp Med. 1992 Jan 1;175(1):91-8
    1. Cell Immunol. 1992 Apr;140(2):513-9
    1. Blood. 1992 Aug 15;80(4):966-74
    1. J Lab Clin Med. 1992 Oct;120(4):574-88
    1. Cell. 1993 May 7;73(3):457-67
    1. J Clin Invest. 1993 Jun;91(6):2850-60
    1. Am J Pathol. 1993 Jul;143(1):76-84
    1. Nouv Rev Fr Hematol. 1992;34 Suppl:S15-27
    1. Proc Natl Acad Sci U S A. 1993 Nov 1;90(21):9887-91
    1. J Clin Invest. 1994 Jan;93(1):114-20
    1. Blood. 1994 Jan 15;83(2):446-51
    1. J Biol Chem. 1994 Jan 14;269(2):1361-9
    1. Am J Pathol. 1994 Jan;144(1):51-9
    1. Biotechniques. 1994 Mar;16(3):405
    1. J Immunol. 1990 Apr 1;144(7):2678-82
    1. Blood. 1990 Jul 15;76(2):361-7
    1. Anal Biochem. 1990 Aug 1;188(2):245-54
    1. Mol Cell Biol. 1994 Jun;14(6):3772-81
    1. Nature. 1994 Jul 21;370(6486):218-20
    1. J Biol Chem. 1994 Aug 19;269(33):20823-5
    1. Proc Natl Acad Sci U S A. 1994 Aug 30;91(18):8602-6
    1. J Biol Chem. 1994 Oct 21;269(42):26363-7
    1. J Immunol. 1994 Nov 15;153(10):4713-20
    1. J Leukoc Biol. 1995 Jan;57(1):174-9
    1. J Virol. 1995 Mar;69(3):1480-4
    1. J Biol Chem. 1995 Feb 24;270(8):3849-57
    1. J Biol Chem. 1995 Mar 31;270(13):7365-74
    1. Thromb Haemost. 1995 Jan;73(1):39-48
    1. Arterioscler Thromb Vasc Biol. 1995 May;15(5):612-21
    1. Thromb Haemost. 1995 Feb;73(2):223-30
    1. FASEB J. 1995 Jul;9(10):883-9
    1. Hepatology. 1995 Aug;22(2):613-9
    1. J Biol Chem. 1995 Nov 3;270(44):26419-32
    1. J Clin Invest. 1996 May 15;97(10):2213-24
    1. J Immunol. 1996 Jun 15;156(12):4969-73
    1. Crit Care Med. 1996 May;24(5):733-42
    1. J Crit Care. 1996 Jun;11(2):77-94
    1. Am J Cardiol. 1967 Sep;20(3):381-91
    1. Anal Biochem. 1976 May 7;72:248-54
    1. Proc Natl Acad Sci U S A. 1979 Nov;76(11):5939-43
    1. J Immunol. 1980 Aug;125(2):606-9
    1. Br J Haematol. 1983 Jan;53(1):85-95
    1. J Clin Invest. 1983 Jun;71(6):1893-6
    1. Science. 1985 Aug 30;229(4716):867-9
    1. J Exp Med. 1986 Mar 1;163(3):740-5
    1. Proc Natl Acad Sci U S A. 1986 May;83(10):3460-4
    1. Proc Natl Acad Sci U S A. 1986 Jun;83(12):4533-7
    1. J Immunol. 1986 Sep 1;137(5):1532-7
    1. Science. 1986 Oct 24;234(4775):470-4
    1. J Exp Med. 1987 Mar 1;165(3):657-63
    1. Mol Cell Biol. 1987 Feb;7(2):725-37
    1. Nature. 1987 Dec 17-23;330(6149):662-4
    1. J Exp Med. 1988 Aug 1;168(2):637-47
    1. Thromb Res. 1989 Feb 1;53(3):231-41
    1. Mol Cell Biol. 1989 Jun;9(6):2567-73
    1. Cell. 1989 Nov 17;59(4):709-17
    1. Proc Natl Acad Sci U S A. 1990 Mar;87(6):2254-8

Source: PubMed

3
Abonnieren